Oramed Granted European Patent

Oramed Pharma, a clinical-stage company, said pre-market Thursday the European Patent Office has granted the company a patent that covers a combination therapy including both insulin and a GLP-1 analog in a single oral capsule. The patent is titled: “Methods and Compositions for Treating Diabetes: Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes.”

Combination therapies of insulin and GLP-1 analogs have been shown to be highly effective at achieving optimal blood sugar control without an increased risk for hypoglycemia.

Patients on a combination therapy regimen have been shown to lose weight during treatment. However, both insulin and GLP-1 analogs are currently only available via injection.

By Kristen Tardella